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Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite intensive treatment,
the prognosis for patients with GBM remains grim with a median survival of only 14.6 months. Immunotherapy has emerged as a
promising approach for treating many cancers and aﬀords the advantages of cellular-level speciﬁcity and the potential to generate
durable immune surveillance. The complexity of the tumor microenvironment poses a signiﬁcant challenge to the development
of immunotherapy for GBM, as multiple signaling pathways, cytokines, and cell types are intricately coordinated to generate
an immunosuppressive milieu. The development of new immunotherapy approaches frequently uncovers new mechanisms of
tumor-mediated immunosuppression. In this review, we discuss many of the current approaches to immunotherapy and focus on
the challenges presented by the tumor microenvironment.
1.Introduction
Glioblastoma multiforme (GBM) (WHO grade IV astrocy-
toma) is the most common and malignant primary brain
tumor in adults. Despite aggressive, multimodal treatment
with maximal surgical resection followed by temozolomide
and radiation, the prognosis for patients with GBM remains
grim with a median survival of 14.6 months and a 3-year
survival rate of only 10% [1]. One formidable challenge
in advancing GBM therapy is the complexity of the GBM
microenvironment [2]. Elucidating the details of GBM
resistance to traditional therapies requires consideration not
only of the intrinsic properties of tumor cells, but also
how these cells interact with neural precursor cells, tumor
stem cells, vascular endothelial cells, stromal cells, astrocytes,
microglia, lymphocytes, extracellular matrix proteins, and
cytokines. It is this dynamic interplay among diverse cell
populations, cytokines, and extracellular matrix proteins
that coordinates GBM tumorigenesis, growth, and invasion.
Eﬀective therapies, therefore, must not only be directly
cytotoxic to a molecularly diverse population of tumor cells
[3], but must also overcome the protumorigenic properties
of the GBM microenvironment.
Immunotherapy is a particularly attractive approach to
cancer treatment as it aﬀords the advantages of cellular
level speciﬁcity and the potential for generating long-term
immune surveillance against cancer cells. The notion of
activating the immune system against cancer has been
around for decades but has recently come to the forefront
with the FDA approval of the ﬁrst therapeutic cancer
vaccine for the treatment of metastatic, castration-resistant
prostate cancer [4]. More recently, ipilimumab, an anti-
CTLA-4 antibody, was approved by the FDA for ﬁrst-
and second-line treatment of unresectable or metastatic
melanoma [5]. Preclinical research is rapidly identifying new
immunological targets leading the way for the development
of powerful combination therapies [6]. In addition, several
immunotherapiesarecurrentlyinclinicaltrialsandmanyare
producing encouraging results in a variety of cancers [7].
Immunotherapy for neoplasms of the central nervous
system (CNS) has been hampered by the traditional belief
that the CNS is immunologically privileged [8]. This theory
was based on reports of a paucity of native antigen-
presenting cells (APCs) in the CNS, the lack of a traditional
lymphatic system, impermeability of the blood-brain barrier
(BBB) to antibodies and lymphocytes [9], low baseline levels2 Clinical and Developmental Immunology
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Figure 1: Normal T cell proliferation and mechanisms of glioma cell immunoresistance. (From top moving clockwise) Normal T cell
proliferation:tumorcellantigensarepresentedbyMHCandcostimulatorymolecules.Mechanismsofimmunosuppression:gliomacellssecrete
factors leading to an immunosuppressive tumor microenvironment. TGFB and PGE-2 downregulate the expression of MHC, restricting
antigen presentation and T cell proliferation. IL-6. IL-10 and VEGF are potent STAT-3 activators, leading to the proliferation of immature
DCs that are not able to function as APCs.These immature DCs also secrete TGFB which aid in the proliferation of immunosuppressiveTreg
cells and STAT-3 positive TH17 cells. Mechanisms of inhibiting T cell proliferation: glioma cells downregulate MHC on their surface leading
to the decreased antigen presentation and decreased T cell proliferation. Downregulation of B7 works via a similar mechanism in that the
costimulatory signal is lost preventing T cell proliferation. Increased expression of B7-H1 and FasL act as proapoptotic signals for T cells.
of major histocompatibility complex (MHC) expression
[10], altered expression of T cell costimulatory molecules
[11], and the observation that tissues engrafted into the CNS
are rejected more slowly than those grafted to other sites [12,
13].Eachoftheseperceivedimpedimentstoimmunotherapy
has subsequently undergone major revisions. Microglia [14],
macrophages, and dendritic cells [15, 16]a c ta sp o w e r f u l
APCs in the CNS. Antigens originating within the CNS
drain in the cerebrospinal ﬂuid through Virchow-Robin
perivascular spaces to nasal and cervical lymph nodes where
theycanbeaccessedbyna¨ ıveTcells[17,18].Subpopulations
of activated T cells expressing integrins, which impart CNS
tropism, such as α4β7, traverse the BBB [19] where they
can act as cytotoxic or helper T cells based on CD8 or
CD4 expression, respectively [20]. There is also evidence
to suggest that na¨ ıve T cells traﬃc to the CNS, especially
when inﬂammation locally increases the permeability of
the BBB [21]. Furthermore, antibodies have been isolated
from the brain, albeit in much lower concentrations than in
plasma [22, 23]. Taken together, these ﬁndings represent an
evolution in our understanding of the interactions between
the CNS and the immune system.
This paradigm shift has generated enthusiasm for a
potential role for immunotherapy in GBM. Despite encour-
aging results in rodent models, however, clinical trials of
immunotherapy for GBM have been largely disappointing
to date. One of the primary impediments to developing
eﬀectiveimmunotherapiesistheaforementionedcomplexity
of the GBM microenvironment (Figure 1). Immunosup-
pressive cytokines such as prostaglandin E2 (PGE-2), TGF-
β, and IL-10 are known to be highly expressed in GBMs
[24, 25]. In addition, tumor-inﬁltrating T cells have been
shown to exhibit an enriched population of CD4+, CD25+,
FoxP3+ regulatory T cells (Tregs) [26]. Expression of the
signal transducer and activator of transcription 3 (STAT3) is
upregulated in GBM and is believed to promote immuno-
supression and serve as a point of convergence for several
protumorigenic pathways [27]. Furthermore, tumor stem
cells have been shown to be immunosuppressive in GBM
[28]. Immune checkpoints, such as programmed cell deathClinical and Developmental Immunology 3
Table 1: Selected clinical trials using cytokine modulation.
Reference Patients Cytokine Immunologic response Clinical response
[58] n = 145
(GBM: 103, AA: 42) TGF-β — Median survival: 39.1mo (10uM dose)
and 35.2mo (80uM dose)
[63] n = 9
Recurrent GBM IL–2 — Enhancement of tumor on MRI
unchanged (6/9)
[64] n = 9
(GBM: 7, AA: 2) IL–2 — PR: 1
[65] n = 12
recurrent GBM IL–2
Increased inﬂammatory
inﬁltrate in biopsied
tumors
PR: 2, SD: 4, Minor response: 4, Overall
survival 58% (6mo) and 25% (1yr)
[69] n = 31
(GBM: 26, AA: 5)
IFN-γ
(n = 14) —
PR: 3 (Treatment group), No diﬀerence
in median survival between treatment
and control groups
[70] n = 40
(GBM: 14, AA: 14, Other: 12) IFN-γ —N o d i ﬀerence in median overall survival
[71] n = 29
(AA: 12, Other: 17) IFN-β — PR: 2, SD: 2
[72] n = 20
(GBM/AA: 15) IFN-β
IFN-β treatment showed
no growth suppression in
ex vivo assays
SD: 3
[73] n = 7
(GBM: 6, Recurrent AA: 1) IFN-β — No response
[75] n = 35
recurrent HGG IFN-α — Median survival: 13.3mo
[76] n = 275
HGG IFN-α —N o d i ﬀerence in survival
[77] n = 9
(GBM: 6, AA: 2, Other 1) IFN-α —C R : 2
[80] n = 12
(GBM: 11, AA: 1) IL–4 Positive Elispot assay No diﬀerence in progression free survival
[142] n = 9
recurrent GBM IL–4 — Survival > 18mo (n = 1)
[84] n = 15
(GBM: 6, AA: 7, Other: 2) I L – 1 2 — P R :4 ,M i x e dr e s p o n s e :1
1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-
4) may also be manipulated by GBM to induce T cell
exhaustion [26, 29]. Finally, there is evidence to suggest
that the GBM microenvironment may divert CD4+ T cell
diﬀerentiation away from a tumor-directed cytotoxic Th1-
mediated response and toward a Th17-mediated chronic
inﬂammatory response [30], which has been shown to be
protumorigenic in other cancers [31].
Identiﬁcation of appropriate tumor antigens and genera-
tion of a strong antitumor immune response against such a
molecularly heterogeneous neoplasm [32]p o s e sac o n s i d e r -
able challenge. This challenge is ampliﬁed by the immuno-
suppressive tumor microenvironment. Here, we review the
current approaches in immunotherapy for GBM, focusing
speciﬁcally on how each approach is aﬀected by the array of
challenges presented by the tumor microenvironment.
2. CurrentApproaches
2.1. Cytokine Modulation. Immune responses in the CNS
exhibit a distinct hierarchy skewed toward antibody re-
sponses and Th2 T cell diﬀerentiation [33–35]. It is believed
that this hierarchy is maintained by the CNS cytokine milieu
[35].IntheGBMmicroenvironment,theantitumorimmune
response is further suppressed by high levels of circulating
immunosuppressive cytokines such as IL-10, TGF-β,a n d
PGE2 as well as membrane-bound proteins such as FasL
and B7-H1 (PD-L1) [36, 37]. The sources of these molecules
and the details of their interactions are yet to be fully
elucidated. It is clear, however, that the cytokine milieu plays
a critical role in coordinating immunosupression in GBM.
Clinical trials using cytokine modulation are summarized in
Table 1.4 Clinical and Developmental Immunology
2.1.1. TGF-β. TGF-β is synthesized in a pre-pro-TGF-β
form and undergoes homodimerization and cleavage by
the convertase family of endopeptidases [38]t op r o d u c e
a C-terminal mature peptide and an N-terminal latency-
associated peptide, which collectively form the small latency
complex [39]. The small latency complex is then secreted
from the cell and associates with speciﬁc binding proteins
to form the large latency complex, which is bound by
components of the extracellular matrix [39, 40]. TGF-β is
activated when it is released from the latency-associated
peptide through one of a number of context-dependent
mechanisms[41].ActivatedTGF-β regulatesgeneexpression
downstream via the SMAD family of transcription factors
[39]. TGF-β synthesis, secretion, and signaling are reviewed
in detail elsewhere [42].
TGF-β promotes immunosuppression in GBM by
inhibiting T cell activation and proliferation, blocking IL-2
production, suppressing activity of NK cells, and promoting
Treg activity [43, 44]. In addition, TGF-β is believed to
promote tumor growth and invasion by sustaining GBM
stem cells [45], promoting angiogenesis [46], and upregu-
lating expression of molecules such as MMP-2, which are
associated with tumor invasion [47]. The involvement of
TGF-βinmultipletumorigenicpathwaysmakesthiscytokine
an enticing target for immunotherapy.
TGF-β expression is increased by radiation both in vitro
[48]a n din vivo [49]. This ﬁnding is of interest because
radiation therapy is a critical component of the tripartite
treatment approach of resection, temozolomide, and radi-
ation which has become standard of care for patients with
GBM [1], and because there is emerging evidence to suggest
that radiation therapy may alter several components of
the immune microenvironment [50–52]. Radiation-induced
activation of TGF-β is believed to be mediated by reactive
oxygen species (ROS), which have been shown to convert
latent TGF-β preferentially to the TGF-β1 isoform [53].
Although this isoform plays a more minor role in GBM
pathogenesis than the TGF-β2 isoform, available evidence
suggests that TGF-β1 promotes immunosuppression [54]
and acts as a mediator of radiation-induced DNA damage
sustained by nontargeted cell populations [55]. In addition,
TGF-β2 has been shown to increase tumor invasiveness by
upregulating MMP-2 expression in glioma cells [56]a n d
evidence from other cell lines suggests that TGF-β1m a y
be an even more powerful inducer of MMP-2 expression
[57].
The results of TGF-β blockade in preclinical models have
been generally promising. The TGF-β2 antisense oligonu-
cleotide trabedersen (AP12009) has been shown to decrease
tumor cell proliferation, inhibit migration, and enhance
the antitumor immune response in vitro. A randomized,
phase IIb clinical trial of trabedersen reported signiﬁcantly
improved tumor control and a trend toward increased 2-
year survival for patients with anaplastic astrocytoma as
compared with standard chemotherapy (temozolomide or
a combination of procarbazine, lomustine, and vincristine)
[58]. This trial did not report improved survival in patients
with GBM, although a subgroup analysis of young patients
with good performance status indicated a trend toward
improved 2- and 3-year survival rates. Of note, the reported
rate of treatment-related adverse events was approximately
20% higher with standard chemotherapy than with trabed-
ersen. Trabedersen is currently in phase III clinical trials for
anaplastic astrocytoma [59]. Understanding the role of TGF-
β in the tumor microenvironment may have implications for
standard therapies as well. For example, given that available
evidence points toward a protumorigenic role for TGF-β, the
addition of TGF-β blockade to adjuvant radiation therapy
may prove prudent [60].
2.1.2. IL-2. IL-2 is a proinﬂammatory cytokine which
promotes T cell activation and Th1 diﬀerentiation while
abrogating the immunosuppressive eﬀects of TGF-β [61].
IL-2 therapy for GBM is complicated by the fact that
high systemic doses of IL-2 are required to reach thera-
peutic concentrations in the CNS [62]. Early trials of IL-2
alone or in combination with IFN-α [63] or lymphokine-
activated killer (LAK) cells [64] attempted to obviate the
severe side eﬀects associated with systemic high-dose IL-
2 therapy by delivering IL-2 intratumorally or intraven-
tricularly; however, the patients in these trials experienced
signiﬁcantadverseeventsresultingfromlocaledema.Amore
recent trial by Colombo et al. used a retroviral vector and
intratumoral implantation of retroviral-producing cells to
deliver combination HSV-TK/IL-2 gene therapy followed by
administration of acyclovir to 12 patients with recurrent
gliomas [65]. This trial reported no major adverse events
and a radiographic response rate of 50%. Evidence from
preclinical models additionally suggests that IL-2 therapy
generates long-lasting immune surveillance, which is capable
of eliminating tumor cells both inside and outside the CNS
[66]. Current approaches to IL-2 therapy for GBM are
focused on combination therapy and strategies for local
delivery [67].
2.1.3. Interferons. Interferons are secreted by immune cells
in response to viruses or other challenges and serve to coor-
dinate the immune response. Alpha interferon (IFN-α), beta
interferon (IFN-β) and gamma interferon (IFN-γ)h a v eb e e n
extensively studied in cancer immunotherapy. These type 1
interferons have speciﬁcally been implicated in coordinating
an antitumor immune response against GBM. A study by
Fujita et al. demonstrated that mice deﬁcient in type 1
interferons, and induced to develop gliomas de novo via p53
knockdown, exhibited enriched populations of tumor inﬁl-
trating myeloid-derived suppressor cells and Tregs as well as
a decrease in the numbers of tumor-inﬁltrating CD8+ T cells
[68]. Despite some preclinical evidence for eﬃcacy against
gliomas, small clinical trials using IFN-γ have been generally
disappointing [69, 70]. Trials of IFN-β have produced mixed
results [71–73]. The eﬃcacy of IFN-β in combination with
temozolomide is currently being investigated [74].
Of the type 1 interferons, IFN-α has been the most
extensively studied in GBM. In a phase III study by Buckner
et al., 214 patients were initially treated with BCNU and
radiation. Patients with radiographically stable disease were
subsequently randomized to treatment with a second courseClinical and Developmental Immunology 5
of BCNU or BCNU and IFN-α. This study demonstrated no
diﬀerence in survival or tumor response with the addition of
IFN-α[75].Unfortunately,therewasasigniﬁcantlyincreased
incidence of side eﬀects, including fever, chills, myalgias,
somnolence, confusion, and exacerbation of neurologic
deﬁcits in patients receiving IFN-α. These ﬁndings were in
contrast with a prior phase II study by the same group,
which reported that IFN-α was associated with radiographic
evidence of tumor regression in 29% of patients and limited
toxicity [76]. A more recent trial of IFN-α in combination
with local BCNU delivery in patients with recurrent GBM
reported 6-month progression-free survival in 2/9 patients
[77]. Of interest, both patients who responded in this
study were in the group receiving the lowest dose of IFN-
α. Therefore, while grade 2 and grade 3 toxicities were
observed somewhat frequently in the higher dose groups,
only two grade 2 events and no events grades 3 or higher
were observed in the treatment group containing the two
responders.
2.1.4. Miscellaneous Cytokines. Many cytokines have been
evaluated for their eﬀectiveness in GBM therapy. TNF-α
knockout mice implanted with GL261 glioma cells have been
shown to harbor a decreased number of tumor-associated
macrophages and exhibit shorter survival [78]. Knowledge
of the role of TNF-α in human gliomas, however, is limited.
IL-4 has been shown to increase in CD8+ tumor-inﬁltrating
Tc e l l si nar a tm o d e l[ 79]. In a small clinical trial by Okada
et al., patients received vaccinations of autologous glioma
cells and ﬁbroblasts retrovirally transfected with TFG-IL4-
Neo-TK [80]. Treatment was well tolerated, but there was no
observed progression-free survival beneﬁt. Locally delivered
IL-12 in preclinical models increases tumor-directed T cell
responses [81], improves survival, and produces variable
development of durable immune surveillance [82]. Tumor
stem cells secreting IL-12 have also been shown to track
migrating glioma cells and prolong survival [83]. Limited
evaluation of IL-12 therapy in clinical trials, however, has
produced mixed results [84]. Granulocyte-macrophage
colony-stimulating factor (GM-CSF) promotes a CD8+
cytotoxic T cell response when combined with antitumor
vaccines [85]. GM-CSF is currently being used as an
adjuvant in a phase II vaccination study of patients with
newly diagnosed GBM [86]. Discovery of T cell populations
producing IL-17 (Th17) [87] and their association with
STAT3 expression in human cancers [88] have recently
generated an interest in deﬁning the role of these cells in
GBM pathogenesis. Early preclinical studies indicate IL-17 is
expressed in GBM, but the signiﬁcance of IL-17 expression
in the tumor microenvironment is yet to be clearly deﬁned
[30].
2.2. Cellular Immunotherapy. Transfer of ex vivo matured
immune cells is showing promising results as a future
immunotherapeutic intervention against malignant glioma.
Initially used as a treatment for melanoma, this strategy
involves infusion of autologous immune cells that were
maturedexvivowithactivityspeciﬁcforgliomacellantigens.
While studies have shown lymphokine-activated killer cells
cannot eﬀectively migrate across the BBB, eﬀector T cells are
able to cross the BBB allowing for a vaccine or IV strategy to
be used [89].
2.2.1. Lymphokine Activated Killer Cells. Lymphokine acti-
vated killer (LAK) cells are autologous peripheral blood
lymphocytes that have been stimulated in vitro with IL-2
[90]. Results of early clinical trials infusing LAK cells directly
into the surgical cavity showed promise for the use of LAK
cells as an immunotherapeutic strategy [64, 91, 92]. The
most encouraging of these early studies, Hayes et al. reported
am e d i a ns u r v i v a li n1 8p a t i e n t so f1 2 . 2m o n t h sc o m p a r e d
with the control group of 6.2 months with minimal toxicity
[93].In2004,Dillmanetal.reportedminimaltoxicityandan
increase in median survival in a trial of 31 patients. Median
survival from the date of original diagnosis was 17.5 months
versus 13.6 months for a control group of 41 contemporary
GBM patients [94]. Of note, LAK cells must be administered
directly to the tumor site since they fail to eﬀectively migrate
from the periphery into the brain [95]. Clinical trials using
LAKs are summarized in Table 2.
2.2.2. Eﬀector T-Cells. Eﬀector T cell therapy involves trans-
fer of autologous cytotoxic T cells (CTLs) speciﬁc for
tumor antigens, which are matured from peripheral blood
mononuclear cells (PBMCs) or T cells from the tumor itself,
to the host. This therapy is based on the theory that T cells
can migrate to the site of a tumor by crossing the BBB, and
selectivelyexertcytotoxiceﬀectsontumorcells.Thisstrategy
has been studied extensively in malignant melanoma with
promising results. Studies in animal models of glioma have
beenpromising.InitialstudiesbyYamasakiandKikuchiused
IL-2 to activate CD8+ T cell clones with target speciﬁcity
against murine malignant brain tumor cells. This strategy
resulted in successful migration of T-cells to the tumor,
cytotoxicactivityagainstthetumor,andasigniﬁcantincrease
in survival after IV infusion [96].
Early clinical studies using ex-vivo-expanded CTLs were
largely disappointing for patients with GBM, however,
more recent studies have shown promise. Tsurushima et al.
reported that activating polyclonal T cells with IL-2 resulted
in two patients with Grade III disease exhibiting complete
tumor regression for at least 5 years with another patient
having a partial regression [97]. A study using GM-CSF
resulted in three of ten patients having at least partial tumor
regression. All patients with a diagnosis of GBM survived
at least one year from the time of adoptive transfer [98].
Another approach has been to genetically modify T cells to
express a chimerical antigen receptor (CAR) for a known
tumor antigen. Kahlon et al. genetically engineered CD8+ T
cells to express CARs for IL-13Rα2 and reported regression
of GBM xenografts [99]. Studies in human GBM have
demonstratedthatCARscanmigratetotumorsinvivo[100].
Furthermore,Ahmedetal.haveshownthatCARstargetedto
HER2 are able to eliminate CD133+ stem cells as well as bulk
tumorcellsinHER2+GBMs[101].ClinicaltrialsusingCTLs
are summarized in Table 3.6 Clinical and Developmental Immunology
Table 2: Selected clinical trials using lymphokine activated killer (LAK) cells.
Reference Patients Immunologic response Clinical response
[64] n = 9
(GBM: 7, AA: 2) —P R : 1
[91] n = 9
HGG
Cultured LAK cells lysed
cultured glioma cells (n = 6) Slight clinical (but not radiologic) improvement.
[92] n = 20
recurrent HGG — Median survival: 63 weeks
[93]
n = 19
(GBM: 5, AA:4, Other
10)
— C R :1 ,P R :2 ,m e d i a ns u r v i v a l( G B M ) :1 5w e e k s
[94] n = 40
recurrent GBM — Median survival: 17.5 months (signiﬁcantly longer than
contemporary patients)
Others: [94, 143–147]
Table 3: Selected clinical trials using cytotoxic T lymphocytes (CTLs).
Reference Patients Immunologic
response
Clinical
response
[97] n = 4
(GBM: 3, AA: 1) —P R : 3
[98] n = 12
(GBM: 6, AA: 1, Other: 5) —P R : 4
Others: [20, 97, 148–154]
2.3.AntigenIdentiﬁcationandTargeting. Targetingoftumor-
speciﬁc antigens is a promising strategy for delivering anti-
tumor immunotherapy. The eﬀectiveness of this approach
remains controversial, however, as many vaccine trials
have not demonstrated a consistent antitumor response
or survival advantage despite increased tumor reactive
cytotoxic T cells [102–105]. One of the challenges facing
therapy directed against single antigens is the ability of a
tumor to alter its antigen expression proﬁle, resulting in
immune editing. Immune editing consists of three phases:
elimination, equilibrium, and escape [106]. The elimination
phaseismaintainedbyimmunosurveillanceofcancercellsby
boththeinnateandadaptiveimmunesystem[107–109].The
equilibrium phase occurs when tumor cells survive the cyto-
toxic pressure exerted by immune cells. Finally, the escape
phaseresultsinuncontrolledtumorgrowthandoftenclinical
manifestations of disease [106]. Often immune escape is
preceded by mutations within cancer cells that facilitate
immune evasion. For example, loss of HLA class I proteins
[110, 111] and decreased response to IFN-γ [108, 112]h a v e
been described in adenomas of the lung and melanoma.
Another major challenge currently limiting antigen-
targeted therapies is the inability to tailor therapy to an
individual tumor’s antigen expression proﬁle. The current
classiﬁcation scheme for glioma does not account for the
molecular diversity of GBM. A new model for classiﬁcation,
reported by Verhaak et al., is a molecular classiﬁcation of
glioblastoma consisting of four clinically relevant tumor
subtypes—classical, mesenchymal, proneural, and neural
[113]. A comprehensive understanding of which antigens are
presentoneachGBMsubtypewouldallowforbettertargeted
immunotherapy.
2.3.1. EGFRvIII. The epidermal growth factor receptor vIII
(EGFRvIII) is a truncated form of the wild-type EGF recep-
tor [114, 115] and is an attractive antigen for immunother-
apy because it is not expressed by normal brain and leads
to enhanced tumorigenicity of the EGFRvIII-expressing cell
[116]. This truncated protein is constitutively active despite
its inability to bind extracellular ligand [117]. Eﬀorts to
target EGFRvIII, however, have been signiﬁcantly hampered
by immune editing [106]. For example, unpublished data
from CDX-110 clinical trials reported the EGFRvIII antigen
was not expressed on recurrent tumors in 20/23 patients
who had been initially treated with the EGFRvIII vaccine
[25].
The novel EGFRvIII epitope exists extracellulary and is
a prime target for monoclonal antibody recognition [118,
119], which stimulates antitumor cytotoxic T cell matura-
tion. EGFRvIII-speciﬁc titers are not found in normal volun-
teers, but are present in patients with EGFRvIII-expressing
cancers, such as adenocarcinomas and gliomas [120, 121].
Early animal studies using vaccination strategies against
EGFRvIII reported increased numbers of tumor-inﬁltrating
CD4+, CD8+, natural killer (NK) cells, and macrophages as
well as a dramatic increase in survival [119, 122–125].
These promising preclinical results lead to early-phase I
studies looking at the use of vaccine strategies against the
EGFRvIII peptide. The ﬁrst study for malignant gliomas
was the Vaccine for Intra-Cranial Tumors I (VICTOR1).Clinical and Developmental Immunology 7
In this study, autologous mature dendritic cells were pulsed
with 500 ug of PEPvIII, which was conjugated with keyhole
limpet hemocyanin (KLH). Following surgical resection and
completion of radiation therapy, all patients were vaccinated
three times; the ﬁrst three patients were dosed with 3 ×
107 mature DCs per vaccine while the remaining patients
were dosed with one third of their DCs per injection. No
serious adverse events were reported and immunological
responses were detected ex vivo. For patients with GBM,
the median time to progression (TTP) was 46.9 weeks and
median survival was 110.8 weeks. These results compare
favorably with patients treated with resection site carmustine
wafers [126]o rt e m o z o l a m i d e[ 1, 121].
The follow-up phase II study, A Complementary Trial
of an Immunotherapy Against Tumor Speciﬁc EGFRvIII
(ACTIVATE) evaluated the eﬃcacy of the PEPvIII-KLH and
granulocyte macrophage-colony stimulating factor (GM-
CSF) [127]. Patients received three vaccinations at two-week
intervals. Similar to the VICTOR1 study, there were no
serious adverse eﬀects and cellular immune responses were
detected ex vivo. The median TTP was 14.2 months and the
median survival was 32 months. Of note, upon histological
examination, recurrent tumors did not express EGFRvIII.
The currently ongoing ACTIVATE II trial was initiated to
evaluate the eﬀectiveness of adding adjuvant PEPvIII-KLH
vaccination therapy to standard of care (resection, temozo-
lomide, and radiation). Of note, temozolomide induces
lymphopenia, theoretically decreasing the eﬃcacy of an
immune-based therapy. Therefore, the EGFRvIII vaccine
(CDX-110) was given on day 21 of the 28 day cycle, allowing
recovery of the immunosuppression caused by temo-
zolamide [128].
2.3.2. IL-13 Receptor α2. The IL-13Rα2 antigen is a promis-
ing target for immunotherapy because it is highly expressed
on glioma cells but not on host CNS cells [129, 130].
However, it should be noted that IL13Rα2 expression is often
heterogeneous[131].InastudybyOkanoetal.,itwasshown
that a novel epitope of IL-13Rα2 induced CD8+ T cells to
secrete IFNγ and lyse IL-13Rα2-expressing glioma cells in
vitro.T h i se ﬀect was only seen in CD8+ T cells expressing
the HLA-A∗0201 allele [132], which 40–50% of Caucasians
and Asians express [133]. To target the IL-13Rα2i nv i v o ,
IL-13 was tagged with a mutated form of the pseudomonas
exotoxin [134–138]. This fused protein (IL-13-PE38QQR),
also termed Cintredekin besudotox (CB), showed promise in
vivo; Kawakamiet al. reported that CB injected intracranially
resulted in both tumor regression and prolonged survival by
164% as compared with control animals [139].
Three phase I studies were undertaken to determine the
safety of intracerebral administration of CB. Pooled results
of the 51 total patients indicated a slight survival advantage
as compared with BCNU wafers. Subsequently, 276 patients
were enrolled in a Phase III study (PRECISE) to determine if
theoverallsurvival,safety,andqualityoflifediﬀerinpatients
receiving the CB via local Convection-enhanced delivery
(CED) compared to patients receiving BCNU wafers. There
was no reported diﬀerence in median survival (36.4 weeks
for the patients receiving CB compared with 35.3 weeks for
the patients receiving Gliadel wafers, P = 0.476) [140, 141].
2.3.3. IL-4 Receptor. IL-4 receptor (IL-4R) is an attractive
target for immunotherapy because tumor cells express a
diﬀerent IL-4R isoform than that which is present on
circulating immune cells. This isoform of the IL-4R is
commonly expressed in human gliomas and not on neural
tissue [178–181]. The type 2 IL-4R signals through the Jak-
STAT pathway, activating the Jak1/Jak2 tyrosine kinases, and
eventually activating the STAT-6 protein, which translocates
to the nucleus and regulates gene expression [182–184]. To
target the IL-4R, IL-4 was fused to pseudomonas exotoxin
(IL-4(38-37)-PE38KDEL) [181,185].Joshi etal.showed that
this construct induces glioma cell death in culture [186].
In vivo studies demonstrated the same construct decreased
the size of implanted human-derived glioma tumors (U251)
with all treated mice showing complete regression. The
tumors recurred in 50% of animals but were smaller than
tumors harbored by control animals [187].
A phase I clinical trial of the IL-4-fused protein (cpIL4-
PE) was performed in patients with recurrent malignant
gliomas. The construct was injected intratumorally by CED.
The authors concluded that direct glioma injection of cpIL4-
PE was safe, had no systemic toxicity, and caused necrosis
of malignant gliomas that were refractory to conventional
therapy. Subsequent clinical trials using the same construct,
with stereotactic injection as the delivery method, showed
similar ﬁndings of safety and eﬃcacy [142].
In addition to identifying appropriate epitopes, an eﬀec-
tiveimmunotherapystrategymustbeabletoeﬃcientlytarget
these antigens in vivo. Dendritic cell, autologous tumor cell,
and heat shock protein vaccines are discussed below with
general principles illustrated in Figure 2.
2.3.4. Dendritic Cells. Dendritic cells (DCs) are “profes-
sional” antigen-presenting cells (APCs) that activate innate
and adaptive immune responses [155]. Strategies using DCs
seek to exploit this ability as GBM cells are unable to reliably
present antigens to the immune system [188, 189]. DCs
can be harvested from peripheral blood or bone marrow,
pulsed with tumor lysate or tumor-speciﬁc peptides, and
after maturation, injected back into the patient.
InaphaseItrial,Yuetal.expandedperipheralbloodcells
ex vivo into DCs and pulsed them with peptides eluted from
the surface of cultured autologous brain tumor cells. Seven
patients received three biweekly intradermal vaccinations of
peptide-pulsed DCs with no systemic side eﬀects. The vac-
cination led to signiﬁcant T-cell-speciﬁc cytotoxicity against
glioma tumor cells and later biopsy showed that cytotoxic
and memory T cells were able to traﬃc into the tumor
[155]. Liau et al. reported a series of 12 patients treated with
1, 5, and 10 million autologous dendritic cells pulsed with
autologous tumor peptides. Similar to the previous studies,
no systemic side eﬀects were seen and survival was improved
compared to historical controls. Of note, the magnitude of
the T cell inﬁltration was inversely correlated with TGF-
β expression within the tumor microenvironment [156].8 Clinical and Developmental Immunology
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Figure 2: Vaccine Strategies for GBM. (From Left) Dendritic cell vaccine: peripheral blood mononuclear cells are isolated from the patient
and cultured ex vivo. Cytokines are added to culture to activate the DCs. The matured DCs are pulsed with tumor antigen and then added to
the vaccine preparation. Autologous tumor cell vaccine: after tumor removal, tumor cells are cultured. In some cases, these cells are modiﬁed
(e.g., radiation, chemical) and then injected back into the patient. Heat shock protein vaccine: after tumor removal, tumor cells are cultured
and speciﬁc heat shock proteins (e.g., Gp96) are isolated and puriﬁed. The proteins are then added to the vaccine preparation and injected
into the patient.
Alargertrialshowed8of19patientswithGBMhadamedian
survival of 33.6 months with a median time to progression of
18.1 months, surpassing that of historical controls receiving
standard of care. Of note, 42% of patients have survived
longer than 4 years [190].
Pulsing DCs with whole tumor lysate increases the
number of targeted epitopes and prevent antigen-loss escape
and immune editing [191]. Parajuli et al. reported that DCs
pulsed with apoptotic tumor cells or total tumor RNA led
to a more robust immune response compared to DCs pulsed
with tumor cells or fused with glioma cells [192]. Clinical
trials using dendritic cells are summarized in Table 4.
2.3.5. Autologous Tumor Cells. The use of autologous tumor
cells (ATCs) as an immunotherapeutic approach has gar-
nered attention due to the ability to activate the immune sys-
tem with an increased number of potential glioma antigens.
SeveralstrategiesforATCvaccineshavebeentestedincluding
using irradiated glioma cells that were either autologous or
allogenic. The autologous strategy was more beneﬁcial in
providing the most relevant antigens to the patient’s tumor
[193–195]. Recent clinical trials have shown this method
can be used without systemic side eﬀects. Schneider et al.
reported 11 patients who received an autologous tumor vac-
cine with cells modiﬁed with Newcastle-Disease-Virus after
surgery and radiation. Survival was no diﬀerent compared
to patients receiving surgery, radiation, and chemotherapy.
No side eﬀects were seen with the vaccine group [174].
A similar trial by Steiner et al. reported 23 patients who
underwent surgery, radiation, and vaccination. There was a
statistically signiﬁcant increase in median progression-free
survival (40 weeks versus 26 weeks in controls) and median
overall survival of vaccinated patients (100 weeks versus 49
weeksincontrols)[175].Usinganautologousformalin-ﬁxed
tumor vaccine, which is thought to preserve the antigenicity
of the tumor cells, Ishikawa et al. studied 24 patients who
received surgery, and radiation, showing no adverse events
[176]. Selected clinical trials using ATCs are summarized in
Table 5.
2.3.6. Heat Shock Proteins. Heat shock proteins (HSPs)
are chaperon proteins that aid in protein folding and areClinical and Developmental Immunology 9
Table 4: Selected clinical trials using dendritic cells (DCs).
Reference Patients Immunologic response Clinical response
[155] n = 7
(GBM: 6, AA: 1)
Cytotixic and memory T cells found in
recurrent tumor bulk
Median survival: 455 days
(Control group: 257 days)
[156] n = 12
( G B M :7 ,R e c u r r e n tG B M :5 )
Cytotoxicity against autologous tumor
cells. Cytotoxic T cells found in recurrent
tumor bulk.
Median TTP: 19.9mo
(P = 0.028),
Median survival: 35.8mo
(P = 0.006)
[157] n = 18
EGFRvIII expressing GBM
82% of recurrent tumors lost EGFRvIII
expression
Median survival: 26mo
(P = 0.001)
Others: [80, 84, 158–173]
Table 5: Selected clinical trials using autologous tumor cells (ATCs).
Reference Patients Immunologic response Clinical response
[174] n = 11
recurrent GBM Local skin reaction Median survival: 46 weeks
[175] n = 23
GBM
Delayed-type hypersensitivity, increased
memory T cells, increased CD8+ T cells
in recurrent tumors
Median progression free survival: 40 weeks,
median survival 100 weeks
[176] n = 12
GBM — CR: 1, PR: 1, minor response: 2, median
survival: 10.7mo
Table 6: Selected clinical trials using heat shock proteins (HSP).
Reference Patients Immunologic
response Clinical response
[177] n = 12
recurrent GBM — Median survival:
10.5mo
implicated in mediating adaptive and innate immune
responses [195]. While there are ﬁve major families of HSPs,
the HSPs Grp 96, HSP 90, HSP 70, HSP 110, and HSP
170 are considered the most immunogenic [196, 197]. HSPs
aid in the folding of many proteins within the cell, and,
therefore, a speciﬁc target antigen is not required, thus
decreasing the potential for immune editing. Furthermore,
HSPs have been shown to induce human DC maturation
and to activate DCs to secrete proinﬂammatory cytokines
making this strategy an attractive option for immuno-
therapy.
Clinicaltrialsusingavaccine-basedHSPstrategyarecur-
rently underway. In cancers, such as metastatic melanoma,
colorectal carcinoma, chronic myeloid leukemia, and renal
cell carcinoma, HSP vaccines have been shown to be safe
and associated with increased survival [198–201]. Parsa et
al. reported a study in 12 patients with recurrent GBM,
seven of the eight patients treated had a median survival
time of 10.5 months compared to historical controls’ median
of 6.5 months [177]. Currently, two phase I/II clinical
trials using the Grp 96 vaccine strategy are underway
(NCT00293423,NCT00905060).Selectedclinicaltrialsusing
HSPs are summarized in Table 6.
3. Challenges in the Tumor Microenvironment
3.1. Cell Populations. GBM-mediated immunosuppresion
arises from coordinated interactions among the diverse cell
populations, cytokines, and extracellular matrix proteins in
the tumor microenvironment. The nature of these inter-
actions is yet to be fully characterized, but is likely to be
more complex than initially appreciated. For example, it
has been shown that 20–90% of endothelial cells in GBM-
associated vasculature harbor the same mutations as the
tumor cells [202] and that a subpopulation of CD133+
tumor stem cells expresses vascular-endothelial cadherin
(CD144) [203]. Taken together, these ﬁndings indicate that a
signiﬁcant number of GBM-associated endothelial cells may
arise from tumor stem cells [204]. In addition, experiences
with conventional therapies have highlighted how speciﬁc
cell populations give rise to resistance. For example, tumor
stem cells are largely radioresistant. A recent study by
Tamura et al. found that tumors in a cohort of patients
with recurrent grade III and IV gliomas following treatment
with radiosurgery and external beam radiation therapy were
signiﬁcantly enriched for CD133+ cells [205]. Interestingly,
additional cell populations have been implicated in this
phenomenon as well. In vitro studies of GBM stem cell
sensitivity have not clearly demonstrated that these cells
are more radioresistant than CD133− tumor cells [206].
Based on these ﬁndings, Calabrese et al. have proposed
that the resistance of glioma stem cells to radiotherapy
may arise from interactions within the GBM microenviron-
ment [207]. Supporting this theory is the observation that
GBM stem cells tend to reside within perivascular niches,
where interactions with endothelial cells appear to impart10 Clinical and Developmental Immunology
tumor stem cell radioresistance [204, 208]. Other lines
of evidence indicate that extracellular matrix proteins and
hypoxia within the tumor microenvironment may impart
radioresistance in tumor stem cells. These two examples
illustrate the fact that an eﬀective immunotherapy must
not only target tumor cells, but must also disrupt the
immunosuppressive activities of a variety of cell populations
in the tumor microenvironment.
3.2. Cytokines. GBM cell lines have long been known to
express high levels of immunosuppressive cytokines [209].
However, our understanding of the origins of these cytokines
and the roles they play in the tumor microenvironment
represents one of the most signiﬁcant challenges to cytokine-
based therapies for GBM. A recent study by Rodriques
et al. demonstrated that expression of IL-10, TGF-β,a n d
B7-H1 is induced in normal human monocytes after
exposure to GBM cells [37]. TGF-β has also been implicated
in the transformation of vascular endothelial cells to a
proangiogenic phenotype characteristically associated with
GBM [46]. Other studies indicate that TGF-β and IL-10
are more highly expressed in CD133+ than in CD133−
glioma cells and that elevated expression of these cytokines
speciﬁcallywithintumorstemcellpopulationcorrelateswith
ap o o r e rp r o g n o s i s[ 45, 210] .I no r d e rt of u l l yu n d e r s t a n d
the relationship between speciﬁc cytokines and the variety
of cell populations present in the GBM microenvironment,
subclassiﬁcation of these cell populations may be necessary.
For example, it has been suggested that the level of TGF-β
expression as well as the eﬀects of TGF-β signaling may vary
among cancer stem cell subtypes [211]. Another recent study
has shown that exposing GBM cells to IFN-γ decreased
TGF-β but increased expression of PD-1 ligand and
Indoleamine-2,3-Dioxygenase (IDO) [212]. It is reasonable
to speculate that other immunosuppressive cytokines exhibit
comparably complex interactions.
4. Therapies Directedat
t h eI m m un eM ic r oe n vir o n m e n t
4.1. STAT3 Blockade. STAT3 is a member of the signal
transducer and activator of transcription (STAT) family
of transcription factors. The detailed activities of STAT3
in cancer are reviewed elsewhere [213]. In brief, STAT3
is activated when Janus kinases (JAKs) phosphorylate the
cytoplasmic tail of activated IL-6 family cytokine receptors
[214]. The phosphorylated receptor then recruits STAT1 and
STAT3 via the Src homology 2 (SH2) domain of the STAT
protein [214, 215]. JAK tyrosine kinase activity subsequently
phosphorylates STAT3 on Tyr 705, leading to formation
of a phosphorylated-STAT3 (p-STAT3) homodimer which
translocates to the nucleus and binds several promoters
which regulate cytokine expression, cell diﬀerentiation,
proliferation, apoptosis, and angiogenesis [216–219]. Con-
stitutive activation of STAT3 has been implicated in the
tumorigenesisofmanycancersbothinsideandoutsideofthe
CNS and has been shown to be suﬃcient to transform cells
to a malignant phenotype in vitro [220].
Some authors have reported that p-STAT3 is present
in high levels in GBM cell lines [221] and in greater than
75% of tumor tissue samples [222]; however, other authors
have failed to corroborate these ﬁndings [27]. In tumors
exhibiting high levels of STAT3 activity, this transcription
factor has emerged as a critical convergence point for many
pathways known to be associated with GBM growth and
invasion. In addition, increased STAT3 activation has been
correlatedwithshorteroverallsurvivalinacohortofpatients
with GBM [222].
Numerous lines of evidence indicate a protumorigenic
role for STAT3 in the GBM microenvironment. STAT3
activation has been shown to be increased in GBM under
hypoxic conditions, leading to elevated expression of proan-
giogenic factors such as vascular endothelial growth factor
(VEGF) and hypoxic inducible factor-1 (HIF-1) [223].
Furthermore, STAT3 inhibition results in a reduction in
endothelial cell tube formation in vitro [216, 223]. STAT3
has also been implicated in tumor invasion and suppression
of apoptosis. For example, Chen et al. recently demonstrated
that STAT3 inhibition reduces expression of the proinvasive
factor matrix metalloprotease-2 (MMP-2) and the antiapop-
totic factors Bcl-xL and survivin [224]. STAT3 is also critical
for maintaining tumor stem cells [225]. A recent study
by Villalva et al. demonstrated that siRNA knockdown or
inhibition of STAT3 with the small molecule inhibitor Stattic
led to decreased GBM stem cell proliferation and inhibited
neurosphere formation [226]. In addition to its roles in
angiogenesis,tumorinvasion,apoptosis,andmaintenanceof
tumor stem cells, STAT3 is known to act as a potent inhibitor
of both innate [227]a n da d a p t i v e[ 228] immune responses.
STAT3 also induces tolerance via Treg activity, potentially
through an HIF-1-mediated mechanism [229].
Although STAT3 has been most extensively studied as
a tumor-promoting factor in GBM, evidence has recently
emerged to suggest that it may act alternately as a protu-
morigenic factor or a tumor suppressor based on the genetic
background of the tumor [230]. The theory that STAT3 may
exert tumor-suppressing eﬀects in GBM originated from the
observation that STAT3 plays a prominent role in astrocyte
diﬀerentiation [231, 232]. Studies of STAT3−/− astrocytes
have demonstrated that these cells exhibit increased prolif-
eration and invasion, although this mutation is not suﬃcient
to produce malignancy [230]. In addition, STAT3 suppresses
malignant transformation of astrocytes deﬁcient in PTEN
in an orthotopic transplant model in SCID mice [230]a n d
a correlation between PTEN mutation and low levels of
STAT3 activity has also been reported in human GBMs
[233]. Conversely, STAT3 appears to be protumorigenic in
EGFRvIII-expressing tumors [230]. The details of STAT3’s
interaction with EGFRvIII are currently unknown; however,
evidence from breast cancer cell lines suggests that EGFRvIII
maytranslocatetothenucleusandalterthebindingofSTAT3
to DNA [234].
The multiplicity of pro-oncogenic eﬀects ascribed to
STAT3 makes this transcription factor an attractive target
for immunotherapy. Strategies to block STAT3 in GBM have
focused primarily on direct inhibition using RNA interfer-
ence and small molecule inhibitors or indirect inhibitionClinical and Developmental Immunology 11
by targeting upstream kinases or regulatory SOCS proteins
[221, 235–237]. Although STAT3 inhibition has yielded
promising results in vitro, applying this approach to animal
models of GBM has produced mixed outcomes. In light of
the ﬁnding that STAT3 may be alternately protumorigenic or
suppressive to tumor growth, additional research is needed
to elucidate the role of STAT3 in a variety of genetic contexts,
including the background genotype of the host.
Even if the correct patients are identiﬁed, the tumor
microenvironment may pose a number of additional chal-
lenges to eﬀective GBM therapy with STAT3 blockade.
For example, although inhibiting STAT3 may overcome
some of the immunosuppressive mechanisms employed by
GBM, immune cells must still eﬃciently identify appropriate
tumor-speciﬁc antigens in order to avoid immune editing. In
addition,evidencehasalreadyemergedtosuggestthatcancer
stem cells express a diﬀerent immunosuppressive cytokine
proﬁle in response to STAT3 blockade than bulk tumor cells
[238].Thisﬁndinghighlightstheprinciplethatitwillbecrit-
ical to consider the eﬀects of STAT3 inhibition on cytokine
expression and signaling in the variety of cell populations
present in the GBM microenvironment individually as well
asinaggregate.EvenifSTAT3inhibitionresultsingeneration
of an antitumor immune response, this activity may be
thwarted by activation of immune checkpoints such as PD-
1[ 29] and CTLA-4 [26]. Other barriers to STAT3 inhibition
in the treatment of brain tumors include identifying small
molecule inhibitors that can either cross the blood-brain
barrier or be delivered locally. Nevertheless, STAT3 remains
one of the most promising targets in immunotherapy for
GBM and at least one small molecule inhibitor, WP1066, is
currently in preclinical development.
4.2. Regulatory T Cell Depletion. Tregs are a CD25+, FoxP3+
subset of CD4+ helper T cells which suppress immune
activation through interactions with T cells, B cells, NK cells,
DCs, and macrophages [239–243]. Tregs have been shown
to express CTLA-4, to decrease the secretion of IL-2 and
IFN-γ [244], and to skew the immune response away from a
cytotoxic Th1-mediated response in favor of a Th2 response
[245]. Studies of human GBM tissue samples have reported
tumor-inﬁltrating lymphocyte populations signiﬁcantly
enrichedforTregs[26].GBMcellsalsoappeartosecretehigh
levels of CCL22 and CCL2, which facilitates Treg traﬃcking
to the tumor [246]. In addition, high-grade gliomas have
been reported to exhibit a higher density of Tregs than low-
grade tumors [247]. These observations have led to interest
in developing immunotherapies for GBM that target Tregs.
Tregs have been shown to be associated with a number
of other known immunomodulatory pathways [248]. For
example, the STAT3 inhibitor WP1066 has been shown to
decrease Treg proliferation. In addition, CTLA-4 blockade
may abrogate the immunosuppressive eﬀects of Tregs in the
tumor microenvironment without directly inhibiting their
immunosuppressive properties [249–251]. Direct inhibition
of Tregs is also possible with anti-CD25 antibodies and
has been shown to improve survival in mouse glioma
models [252]. A number of other approaches have also been
proposed to inhibit Tregs in gliomas. These approaches are
reviewed in detail elsewhere [253].
Indirect evidence for the eﬃcacy of Treg depletion in
human glioma comes from combining immunotherapy with
cyclophosphamide,whichpreferentiallyinhibitsTregactivity
at low doses [254]. Clinical trials combining cyclophos-
phamidewithadendriticcellvaccineforrenalcellcarcinoma
[255] or with a protein antigen vaccine for breast cancer
[256] have demonstrated that the addition of cyclophos-
phamide augmented the antitumor eﬀect. Blocking antibod-
ies against CTLA-4 [249] and CD25 [252] have been shown
to be eﬀective against gliomas in mice; however, neither of
these approaches has been evaluated in clinical trials.
One of the primary challenges impeding the develop-
ment and implementation of Treg depletion for treatment of
GBM is precisely delineating how these cells interact with the
otherimmunosuppressivefactorsinthetumorenvironment.
Despitenumerouslinesofevidenceimplicatingaprotumori-
genic role for Tregs, and the theoretical appeal of these cells
as targets for immunotherapy, fundamental questions about
the role of Tregs in GBM tumorigenesis remain unanswered.
For example, several studies have failed to convincingly
correlate the density of tumor-inﬁltrating lymphocytes with
prognosis in human gliomas [257–259]. Because these
studies did not account for lymphocyte activity, it has been
proposed that local immunosuppression in GBMs results
from inhibition of T cell function secondary to an enriched
population of Tregs [247]. Studies directly evaluating the
relationship between Treg fractions and survival in patients
with GBM, however, have not demonstrated a reliable
correlation [260].
T r e g sh a v eb e e ni m p l i c a t e di na s s o c i a t i o nw i t hm a n y
other known immunosuppressive factors in the GBM
microenvironment, such as CTLA-4 and STAT3. The lack
of a clearly deﬁned mechanism underlying the interactions
between Tregs and CTLA-4, however, precludes the devel-
opment of maximally eﬀective combination therapies. The
ﬁndingthatSTAT3blockadeinhibitsTregfunctionisintrigu-
ing and deserves further exploration. In particular, STAT3
signaling may coordinate the activities of Tregs with other
cell populations in the tumor microenvironment, including
tumor stem cells [238]. Ultimately, deﬁning the roles of
TregsinGBMrepresentsacriticalsteptowardunderstanding
the mechanisms underlying the immunosuppressive tumor
microenvironment and may serve as a valuable target for
intervention.
5. Conclusion
We have reviewed challenges presented by the tumor
microenvironment and many of the current approaches to
immunotherapy for GBM. It is becoming increasingly clear
that GBM-mediated immunosuppression arises not only
from the intrinsic properties of tumor cells, but from the
ability of these cells to coordinate the activities of a diverse
set of cell types and signaling pathways in the tumor
micro-environment. Therefore, the development of eﬀective
immunotherapies will require careful study of how inter-
vening at any point in this system alters the dynamics of12 Clinical and Developmental Immunology
these interactions. For example, the ﬁnding that treatment
with IFN-γ increases expression of PD-L1 demonstrates
potentially redundant immunosuppressive mechanisms. The
diﬀerential eﬀects of STAT3 blockade based on tumor
genetics highlights the importance of developing molecular
classiﬁcation schemes that reﬂect responsiveness to various
immunotherapy approaches. Furthermore, the ﬁnding that
tumor stem cells may diﬀerentiate into vascular endothelial
cells suggests potential interactions between tumor endothe-
lial cells and immune cells that have not yet been elucidated.
With these challenges, however, comes enormous potential
to precisely target the defense mechanisms in GBM and tip
the balance back in favor of the immune system.
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